Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2001 Mar;56(3):167–172. doi: 10.1136/thorax.56.3.167

First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol

C Research
PMCID: PMC1758783  PMID: 11182006

Abstract

BACKGROUND—The treatment of pulmonary disease caused by opportunist mycobacteria is controversial. It is uncertain whether in vitro sensitivity testing predicts clinical response in the way it does for Mycobacterium tuberculosis. The literature suggests that the combination of rifampicin (R) and ethambutol (E) is important whereas isoniazid (H) may not be, but to date there have been no published reports of randomised controlled trials in the treatment of these conditions. The British Thoracic Society has conducted the first such trial, a randomised study of two regimens in HIV negative patients with pulmonary disease caused by M avium intracellulare (MAC), M malmoense, and M xenopi.
METHODS—When two positive cultures were confirmed by the Mycobacterium Reference Laboratories for England, Wales and Scotland, the coordinating physician invited the patient's physician to enrol the patient. Patients were also recruited from Scandinavia. Randomisation to 2 years of treatment with RE or REH was performed from lists held in the coordinator's office. Clinical, bacteriological, and radiological progress was monitored at set intervals up to 5years.
RESULTS—From October 1987 to December 1992, 141 physicians entered 223 patients (106 with M malmoense, 75 with MAC, 42 with M xenopi). At entry the RE and REH groups were comparable over a range of demographic and clinical features. For each species there was no significant difference between RE and REH in the number of deaths, but when the three species were combined there were fewer deaths from the mycobacterial disease with RE (1% v 8%, p=0.018, odds ratio 0.10, exact 95% CI 0.00 to 0.76). For M malmoense the failure of treatment/relapse rates did not differ appreciably between the regimens, but for MAC there were fewer failures of treatment/relapses with REH (16% v 41%, p=0.033) With M xenopi there was a non-significant trend in the same direction (5% v 18%, p=0.41) and when all three species were combined there was a significant difference in favour of REH (11% v 22%, p=0.033). There was no correlation between failure of treatment/relapse and in vitro resistance. M xenopi was associated with the greatest mortality (57% at 5 years), MAC was the most difficult to eradicate, and M malmoense had the most favourable outlook (42% known to be alive and cured at 5years).
CONCLUSIONS—The results of susceptibility tests performed by the modal resistance method do not correlate with the patient's response to chemotherapy. RE and REH are tolerated better than previous regimens containing second or third line anti-mycobacterial drugs. Treatment of M malmoense with RE for 2 years is preferable to REH. The addition of H reduces the failure of treatment/relapse rates for MAC and has a tendency to do so also for M xenopi, but there is a suggestion that REH is associated with higher death rates overall. Better regimens are required.



Full Text

The Full Text of this article is available as a PDF (143.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banks J., Hunter A. M., Campbell I. A., Jenkins P. A., Smith A. P. Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax. 1984 May;39(5):376–382. doi: 10.1136/thx.39.5.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Banks J., Jenkins P. A. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax. 1987 Nov;42(11):838–842. doi: 10.1136/thx.42.11.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Banks J., Jenkins P. A., Smith A. P. Pulmonary infection with Mycobacterium malmoense--a review of treatment and response. Tubercle. 1985 Sep;66(3):197–203. doi: 10.1016/0041-3879(85)90037-6. [DOI] [PubMed] [Google Scholar]
  4. Bates J. H. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration-armed forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis. 1967 Dec;96(6):1151–1157. doi: 10.1164/arrd.1967.96.6.1151. [DOI] [PubMed] [Google Scholar]
  5. Chaisson R. E., Benson C. A., Dube M. P., Heifets L. B., Korvick J. A., Elkin S., Smith T., Craft J. C., Sattler F. R. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec 15;121(12):905–911. doi: 10.7326/0003-4819-121-12-199412150-00001. [DOI] [PubMed] [Google Scholar]
  6. Contreras M. A., Cheung O. T., Sanders D. E., Goldstein R. S. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis. 1988 Jan;137(1):149–152. doi: 10.1164/ajrccm/137.1.149. [DOI] [PubMed] [Google Scholar]
  7. Costrini A. M., Mahler D. A., Gross W. M., Hawkins J. E., Yesner R., D'Esopo N. D. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. 1981 Jan;123(1):104–109. doi: 10.1164/arrd.1981.123.1.104. [DOI] [PubMed] [Google Scholar]
  8. Dautzenberg B., Piperno D., Diot P., Truffot-Pernot C., Chauvin J. P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995 Apr;107(4):1035–1040. doi: 10.1378/chest.107.4.1035. [DOI] [PubMed] [Google Scholar]
  9. Dutt A. K., Stead W. W. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med. 1979 Sep;67(3):449–453. doi: 10.1016/0002-9343(79)90792-7. [DOI] [PubMed] [Google Scholar]
  10. Etzkorn E. T., Aldarondo S., McAllister C. K., Matthews J., Ognibene A. J. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis. 1986 Sep;134(3):442–445. doi: 10.1164/arrd.1986.134.3.442. [DOI] [PubMed] [Google Scholar]
  11. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. France A. J., McLeod D. T., Calder M. A., Seaton A. Mycobacterium malmoense infections in Scotland: an increasing problem. Thorax. 1987 Aug;42(8):593–595. doi: 10.1136/thx.42.8.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gay J. D., DeYoung D. R., Roberts G. D. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother. 1984 Jul;26(1):94–96. doi: 10.1128/aac.26.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Griffith D. E., Brown B. A., Cegielski P., Murphy D. T., Wallace R. J., Jr Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000 Feb;30(2):288–292. doi: 10.1086/313644. [DOI] [PubMed] [Google Scholar]
  15. Heifets L. B. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis. 1982 Jan;125(1):43–48. doi: 10.1164/arrd.1982.125.1.43. [DOI] [PubMed] [Google Scholar]
  16. Heurlin N., Petrini B. Treatment of non-tuberculous mycobacterial infections in patients without AIDS. Scand J Infect Dis. 1993;25(5):619–623. doi: 10.3109/00365549309008551. [DOI] [PubMed] [Google Scholar]
  17. Hoffner S. E., Hjelm U., Källenius G. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother. 1993 Jun;37(6):1285–1288. doi: 10.1128/aac.37.6.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hoffner S. E., Svenson S. B., Källenius G. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol. 1987 Oct;6(5):530–535. doi: 10.1007/BF02014241. [DOI] [PubMed] [Google Scholar]
  19. Huang J. H., Kao P. N., Adi V., Ruoss S. J. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999 Apr;115(4):1033–1040. doi: 10.1378/chest.115.4.1033. [DOI] [PubMed] [Google Scholar]
  20. Hunter A. M., Campbell I. A., Jenkins P. A., Smith A. P. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax. 1981 May;36(5):326–329. doi: 10.1136/thx.36.5.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leysen D. C., Haemers A., Pattyn S. R. Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989 Jan;33(1):1–5. doi: 10.1128/aac.33.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. MARKS J. The design of sensitivity tests on tubercle bacilli. Tubercle. 1961 Sep;42:314–316. doi: 10.1016/s0041-3879(61)80114-1. [DOI] [PubMed] [Google Scholar]
  23. Pierce M., Crampton S., Henry D., Heifets L., LaMarca A., Montecalvo M., Wormser G. P., Jablonowski H., Jemsek J., Cynamon M. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996 Aug 8;335(6):384–391. doi: 10.1056/NEJM199608083350603. [DOI] [PubMed] [Google Scholar]
  24. Rosenzweig D. Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest. 1979 Feb;75(2):115–119. doi: 10.1378/chest.75.2.115. [DOI] [PubMed] [Google Scholar]
  25. Shafran S. D., Singer J., Zarowny D. P., Phillips P., Salit I., Walmsley S. L., Fong I. W., Gill M. J., Rachlis A. R., Lalonde R. G. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med. 1996 Aug 8;335(6):377–383. doi: 10.1056/NEJM199608083350602. [DOI] [PubMed] [Google Scholar]
  26. Smith M. J., Citron K. M. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax. 1983 May;38(5):373–377. doi: 10.1136/thx.38.5.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tanaka E., Kimoto T., Tsuyuguchi K., Watanabe I., Matsumoto H., Niimi A., Suzuki K., Murayama T., Amitani R., Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999 Sep;160(3):866–872. doi: 10.1164/ajrccm.160.3.9811086. [DOI] [PubMed] [Google Scholar]
  28. Wallace R. J., Jr, Brown B. A., Griffith D. E., Girard W. M., Murphy D. T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1766–1772. doi: 10.1164/ajrccm.153.6.8665032. [DOI] [PubMed] [Google Scholar]
  29. Yeager H., Jr, Raleigh J. W. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis. 1973 Sep;108(3):547–552. doi: 10.1164/arrd.1973.108.3.547. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES